Cancer Immunotherapy Conference San Diego 2027

Why San Diego, why February

A cancer immunotherapy conference in San Diego, timed for new budgets

The ImmunoMark Summit West Coast Edition is a cancer immunotherapy conference in San Diego on February 10–11, 2027, and its Stream 1, Next-Gen Immuno-Oncology, is built around the next-generation programs your sales team is trying to reach: cell therapies beyond CAR-T, in vivo cell engineering, cancer vaccines and tumor microenvironment work.

This is the launch edition, with 300+ senior attendees expected. For an IO tool vendor, immune-monitoring lab, cell therapy supplier or CRO, three things make it worth a look before the rest of your 2027 calendar fills up.

The West Coast IO cluster

The summit is hosted in one of the world’s leading biotech and life sciences hubs, with a Stream 1 panel dedicated to “The Future of Precision Immuno-Oncology Across the West Coast Innovation Ecosystem”. Your field team can cover San Diego accounts without a flight.

February timing

Mid-February lands after January’s investor and partnering meetings, when program leads have fresh budgets and are turning plans into vendor shortlists. An immuno-oncology conference in February 2027 catches them at that point.

Launch-edition position

Booking early for a first edition gives you the widest choice of talk slots and booth positions. The organizer, Convolign Business Consulting, ran the first London edition in 2026, where sponsors held 15–25 meetings each.

Stream 1 program

What the immunotherapy summit San Diego 2027 program covers

These are real Stream 1 sessions from the San Diego agenda. Titles are quoted as published.

Day 1 · Stream 1The Use of Artificial Intelligence and Machine Learning in Accelerating Immuno-Oncology Drug Discovery
Day 1 · Stream 1Challenges of Efficacy and Safety when Combining Immuno-Oncology Agents with ADCs (Rakesh Dixit, Regio Biosciences)
Day 1 · Stream 1Advancing Next-Generation Cell Therapies Beyond CAR-T for the Treatment of Solid Tumours
Day 1 · Stream 1The Future of In Vivo Cell Engineering and Gene Editing Technologies in Cancer Immunotherapy
Day 1 · Stream 1Reprogramming the Tumour Microenvironment to Overcome Resistance to Cancer Immunotherapy
Day 1 · Stream 1Personalised Cancer Vaccines and Neoantigen Discovery for Next-Generation Immunotherapies
Day 1 · Stream 1Computational Immunology and Digital Twin Technologies for Precision Cancer Treatment
Day 2 · Stream 1Emerging NK Cell, TIL and In Vivo CAR Platforms Reshaping Cancer Immunotherapy
Day 2 · Stream 1RNA Therapeutics and Gene Editing Technologies for Next-Generation Cancer Treatments
Day 2 · Stream 1Harnessing the Human Microbiome to Enhance Immunotherapy Response and Patient Outcomes
Day 2 · Stream 1Artificial Intelligence for Optimising Clinical Trial Design and Patient Selection

Read as a buyer map, the program clusters into four groups: engineered and in vivo cell therapies (the strongest fit for vector, gene-editing and cell-processing suppliers), tumor microenvironment and resistance (immune-monitoring and profiling labs), vaccines and neoantigens (antigen discovery and T cell assay providers), and AI and computational immunology (data and trial-design partners). If in vivo CAR-T is your market, our in vivo CAR-T overview is useful background.

Buyer roles

Who is on the Stream 1 speaker panel, and what their teams buy

Roles below are taken from the San Diego Immuno-Oncology speaker panel. The middle column describes the typical remit of that role, not a statement of any individual’s plans.

Role and company (as listed)	Typical remit	Vendors who should request a 1:1
Director, Cell Therapy Product Development, ImmunityBio, Inc.	Process development and product characterization	Cell therapy CDMOs, cell-processing and analytics tools
Head of Analytical Development, ArsenalBio	Potency, release and characterization assays	Assay developers, QC and bioanalytical CROs
Vice President, Head of Translational, Xencor	Translational strategy for engineered antibodies	Immune-monitoring labs, cytokine and receptor-occupancy services
Head of Translational Medicine, Vice President, Janux Therapeutics	Clinical biomarker and pharmacodynamic plans	Central labs, flow cytometry and specialty biomarker labs
Associate Director/Principal Scientist, Translational Medicine, Nkarta, Inc.	Translation of NK cell programs	Cytometry panels, cell-tracking and persistence assays
Director Translational Oncology Bioinformatics, Pfizer	Data integration across translational studies	Computational immunology and data platforms
Head of Asset/Global Development Lead, AbbVie	Clinical development of an asset	IO trial CROs and site networks

Across the event, 55–60% of delegates are expected from biotech and pharma and 45–50% from senior leadership. That is the profile you want for an immuno-oncology meeting in San Diego where partner decisions get made, rather than a poster-hall conversation.

1:1 meetings

How pre-scheduled 1:1 meetings work for an IO vendor

Meetings are the part of the package most IO sponsors measure. Here is the sequence.

Choose your meeting volumeHeadline includes 15 meetings, Platinum 10 and Gold 6. Exclusive 1:1 Meetings packages give 3, 5, 7 or 10 on their own.
Build your target list earlyUse the wishlist feature to flag the program types and roles you want, such as cell therapy CMC, translational medicine or clinical operations.
Pick from the full delegate listTen days before the event you receive the full delegate list with profiles, and choose who you want to meet.
Meet in 20-minute slotsMeetings are scheduled across February 10–11, so your team is not chasing people between sessions.
Follow up the same eveningThe Day 1 drinks reception runs 18:00–19:00, a natural second touch with anyone you met that day.
Work the list after the eventEvery tier includes the delegate list with contact details, plus post-event branding.

Packages

Which package fits an immuno-oncology conference sponsor in California

Platinum, Gold and Silver sponsors choose their stream. For cell therapy and in vivo CAR-T suppliers, the Day 2 Stream 1 schedule is the sweet spot.

Best fit

Gold, Stream 1

Day 2 Gold slots run at 10:00, 11:00 and 12:30, around “Emerging NK Cell, TIL and In Vivo CAR Platforms” at 11:30 and the RNA and gene editing session at 12:00. Your talk lands in front of the exact cell-engineering audience.

30-minute Day 2 talk before lunch, plus Q&A
6 pre-scheduled 1:1 meetings
6 team + 6 client passes, 10 x 6 ft booth
Attendee list a week before

Platinum, Stream 1

Day 1 slots at 11:00, 12:30 and 14:30 sit between the cell therapy, in vivo engineering and tumor microenvironment sessions. Best if you need more meetings and pre-event reach.

30-minute Day 1 talk plus Q&A
10 pre-scheduled 1:1 meetings
8 team + 8 client passes, 10 x 6 ft booth
Email campaign to confirmed delegates, 1-minute video

Exclusive 1:1 Meetings

For CROs and immune-monitoring labs that sell in private conversations and want to test a launch edition.

3, 5, 7 or 10 meetings of 20 minutes
2–4 passes plus drinks reception passes
Wishlist and delegate list with contacts

Full tier details are on the San Diego sponsorship opportunities page. If you also sell in Europe, the London cancer immunotherapy conference follows three weeks later with a different Stream 1 agenda. For preclinical and tumor immunology research buyers in San Diego, see cancer conference San Diego, and for the edition comparison, the immuno-oncology summit page.

Estimate what 6 or 10 meetings with West Coast IO program leads are worth to your pipeline.

Open the ROI calculator

Want Stream 1 slot availability for the launch edition?

Request the prospectus

Sponsorship ROI calculator

What could San Diego 2027 be worth to your team?

Pick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.

1. Choose a package

Sponsorship packages

Exclusive 1:1 meeting packages

2. Your numbers

Average first-year deal value

Year-one value of a new pharma or biotech customer

Extra conversations at the event

Booth visits, networking and questions after your talk

Become a real opportunity

Share of conversations worth a proposal

Opportunities you usually win

Your typical close rate

Your total event budget

Sponsorship plus travel and team costs

Estimated return

expected first-year revenue for every $1 of your event budget

Pre-scheduled 1:1 meetings

Qualified conversations

New opportunities

Cost per conversation

Pipeline created

Expected revenue won

Get pricing and the prospectus for this package Or talk to our team about a custom package

Estimates only, based on the numbers you enter. Meetings and inclusions from the San Diego 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Is a launch edition a risk for an IO sponsor?

It is a first edition, so there is no San Diego track record yet. The organizer, Convolign Business Consulting, ran the first London edition in March 2026: 300+ attendees, 100+ companies, 70% senior decision-makers and 15–25 meetings per sponsor. San Diego expects 300+ senior attendees, and pre-scheduled 1:1 meetings mean your meeting count does not depend on booth traffic.

Which San Diego Stream 1 sessions matter most to cell therapy and in vivo CAR-T suppliers?

On Day 1, 'Advancing Next-Generation Cell Therapies Beyond CAR-T for the Treatment of Solid Tumours' and 'The Future of In Vivo Cell Engineering and Gene Editing Technologies in Cancer Immunotherapy'. On Day 2, 'Emerging NK Cell, TIL and In Vivo CAR Platforms Reshaping Cancer Immunotherapy' and 'RNA Therapeutics and Gene Editing Technologies for Next-Generation Cancer Treatments'.

Can a CRO or immune-monitoring lab get value without a speaking slot?

Yes. The Exclusive 1:1 Meetings packages give 3, 5, 7 or 10 pre-arranged 20-minute meetings chosen from the full delegate list, with 2–4 passes, drinks reception passes, the wishlist feature and the delegate list with contact details.

Why sponsor an immuno-oncology conference in February 2027?

February 10–11 falls early in most companies' budget year, after January's investor and partnering meetings, when IO program leads are shortlisting vendors for the year ahead. It also comes three weeks before the London edition on March 3–4, 2027.

Can we sponsor both San Diego and London?

Yes. Packages are the same at both editions, and Platinum, Gold and Silver sponsors choose their stream at each one. The two Stream 1 agendas are different, so you can match your talk to each audience: San Diego leans toward in vivo engineering, NK and TIL platforms and vaccines, London toward myeloid checkpoints, logic-gated CAR-T and allogeneic cell therapy.

San Diego Cancer Immunotherapy Conference: Launch-Edition Sponsorship

Get the prospectus and package availability